Non-alcoholic fatty liver disease has become the leading chronic liver disease in the developed world, with a prevalence of 6%-35%. Its pathological spectrum ranges from simple steatosis (non-alcoholic fatty liver) to different degrees of inflammation and liver cell damage [non-alcoholic steatohepatitis (NASH)]. NASH has gained attention in recent years because of its association with hepatocellular carcinoma (HCC). Although the occurrence of HCC is more frequent in the presence of cirrhosis, studies have shown that hepatic carcinogenesis may also develop in the context of NASH without association with advanced fibrosis, as well as from simple steatosis. Evidence of the onset of HCC in the absence of cirrhosis is of concern, since recent su...
Abstract Background There are limited data regarding the factors associated with hepatocellular carc...
Nonalcoholic fatty liver disease and its evolutive form nonalcoholic steatohepatitis (NASH) are nowa...
Nonalcoholic fatty liver disease (NAFLD) represents the hepatic manifestation of metabolic syndrome ...
Non-alcoholic fatty liver disease has become the leading chronic liver disease in the developed worl...
Recently, nonalcoholic steatohepatitis (NASH) has been considered to be another cause of liver cirrh...
Non-alcoholic steatohepatitis (NASH) has been associated with hepatocellular carcinoma (HCC) often a...
Hepatocellular carcinoma (HCC) is the sixth most common cancer in world and third largest cause of c...
Introduction: Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumour, whic...
Recently, nonalcoholic steatohepatitis (NASH) has been considered to be another cause of liver cirrh...
Background: Non-alcoholic fatty liver disease (NAFLD) is a global epidemic involving 20-40% of the g...
Non-alcoholic fatty liver disease (NAFLD) affects up to a quarter of the adult population in many de...
The risk of hepatocellular carcinoma (HCC) is increased in patients with metabolic syndrome (MS), po...
Non-alcoholic fatty liver disease (NAFLD) represents the hepatic manifestation of metabolic syndrome...
Abstract Background There are limited data regarding the factors associated with hepatocellular carc...
Nonalcoholic fatty liver disease and its evolutive form nonalcoholic steatohepatitis (NASH) are nowa...
Nonalcoholic fatty liver disease (NAFLD) represents the hepatic manifestation of metabolic syndrome ...
Non-alcoholic fatty liver disease has become the leading chronic liver disease in the developed worl...
Recently, nonalcoholic steatohepatitis (NASH) has been considered to be another cause of liver cirrh...
Non-alcoholic steatohepatitis (NASH) has been associated with hepatocellular carcinoma (HCC) often a...
Hepatocellular carcinoma (HCC) is the sixth most common cancer in world and third largest cause of c...
Introduction: Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumour, whic...
Recently, nonalcoholic steatohepatitis (NASH) has been considered to be another cause of liver cirrh...
Background: Non-alcoholic fatty liver disease (NAFLD) is a global epidemic involving 20-40% of the g...
Non-alcoholic fatty liver disease (NAFLD) affects up to a quarter of the adult population in many de...
The risk of hepatocellular carcinoma (HCC) is increased in patients with metabolic syndrome (MS), po...
Non-alcoholic fatty liver disease (NAFLD) represents the hepatic manifestation of metabolic syndrome...
Abstract Background There are limited data regarding the factors associated with hepatocellular carc...
Nonalcoholic fatty liver disease and its evolutive form nonalcoholic steatohepatitis (NASH) are nowa...
Nonalcoholic fatty liver disease (NAFLD) represents the hepatic manifestation of metabolic syndrome ...